OncoTherapy's lead project set to enter Phase II
This article was originally published in Scrip
The Japanese bioventure OncoTherapy Science is to take its lead development project into Phase II clinical trials later this year following positive results in a domestic Phase I study. OTS102 is an angiogenesis-inhibiting therapy for colon and other cancers, which targets the VEGF receptor 2 over-expressed in tumour blood vessels. Its main component is KDR169, the main kinase domain receptor of VEGFR2, which induces cytotoxic T lymphocytes to attack tumour-associated neovascular endothelial cells expressing KDR. The Phase II programme should begin in the autumn, OncoTherapy said.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.